5 Key Takeaways

• 1

  The FDA approved aminolevulinic acid hydrochloride (Ameluz) for use with photodynamic therapy for superficial basal cell carcinoma.

• 2

  Ameluz is the first FDA-approved photodynamic therapy drug specifically for skin cancer treatment.

• 3

  Superficial basal cell carcinoma accounts for approximately 15% to 20% of the 3.6 million BCC cases diagnosed annually in the US.

• 4

  In a phase 3 trial, 66% of patients treated with Ameluz achieved the primary endpoint compared to 5% in the placebo group.

• 5

  Application-site reactions were the most common adverse effects noted, aligning with the therapy's known safety profile.